SI1230932T1 - Use of antibodies for anticancer vaccination - Google Patents

Use of antibodies for anticancer vaccination

Info

Publication number
SI1230932T1
SI1230932T1 SI200030594T SI200030594T SI1230932T1 SI 1230932 T1 SI1230932 T1 SI 1230932T1 SI 200030594 T SI200030594 T SI 200030594T SI 200030594 T SI200030594 T SI 200030594T SI 1230932 T1 SI1230932 T1 SI 1230932T1
Authority
SI
Slovenia
Prior art keywords
antibodies
anticancer vaccination
vaccination
anticancer
prophylactically
Prior art date
Application number
SI200030594T
Other languages
English (en)
Slovenian (sl)
Inventor
Helmut Eckert
Hans Loibner
Original Assignee
Igeneon Krebs-Immuntherapie Forschungs- Und Entwicklungs-Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Igeneon Krebs-Immuntherapie Forschungs- Und Entwicklungs-Ag filed Critical Igeneon Krebs-Immuntherapie Forschungs- Und Entwicklungs-Ag
Publication of SI1230932T1 publication Critical patent/SI1230932T1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SI200030594T 1999-01-13 2000-01-12 Use of antibodies for anticancer vaccination SI1230932T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH5199 1999-01-13
PCT/EP2000/000174 WO2000041722A1 (de) 1999-01-13 2000-01-12 Verwendung von antikörpern zur vakzinierung gegen krebs

Publications (1)

Publication Number Publication Date
SI1230932T1 true SI1230932T1 (en) 2005-06-30

Family

ID=4178206

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200030594T SI1230932T1 (en) 1999-01-13 2000-01-12 Use of antibodies for anticancer vaccination
SI200030015T SI1140168T1 (en) 1999-01-13 2000-01-12 Vaccination against cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI200030015T SI1140168T1 (en) 1999-01-13 2000-01-12 Vaccination against cancer

Country Status (28)

Country Link
US (3) US7691372B2 (enExample)
EP (2) EP1140168B1 (enExample)
JP (1) JP4774551B2 (enExample)
KR (1) KR100771752B1 (enExample)
CN (1) CN1188169C (enExample)
AT (2) ATE219687T1 (enExample)
AU (1) AU768515B2 (enExample)
CA (1) CA2360382C (enExample)
CZ (1) CZ302801B6 (enExample)
DE (2) DE50009240D1 (enExample)
DK (2) DK1230932T3 (enExample)
EE (1) EE05474B1 (enExample)
ES (2) ES2177509T3 (enExample)
HK (1) HK1044487B (enExample)
HR (1) HRP20010526A2 (enExample)
HU (1) HU226150B1 (enExample)
ID (1) ID30223A (enExample)
IL (2) IL144265A0 (enExample)
IS (1) IS5998A (enExample)
MX (1) MXPA01007148A (enExample)
NO (1) NO329917B1 (enExample)
NZ (1) NZ512722A (enExample)
PL (1) PL201533B1 (enExample)
PT (2) PT1140168E (enExample)
SI (2) SI1230932T1 (enExample)
SK (1) SK286627B6 (enExample)
TR (1) TR200102034T2 (enExample)
WO (1) WO2000041722A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01007148A (es) * 1999-01-13 2002-03-27 Igeneon Krebs Immuntherapie Uso de anticuerpos para vacunacion anti-cancer.
AT410172B (de) 2000-03-21 2003-02-25 Igeneon Gmbh Verfahren zur herstellung einer vakzineformulierung
AT502293B1 (de) * 2002-05-15 2008-03-15 Igeneon Krebs Immuntherapie Immunogener, monoklonaler antikörper
AT500647A1 (de) * 2002-05-21 2006-02-15 Igeneon Krebs Immuntherapie Verwendung eines impfstoffes
AT500650B1 (de) 2003-04-17 2009-11-15 Altropus Gmbh Immunogener rekombinanter antikörper
AT500651B9 (de) * 2003-05-27 2010-04-15 Altropus Gmbh Aktiv immunisierender antikörper
JP2008505943A (ja) 2004-07-14 2008-02-28 イゲネーオン・クレープス−イムンテラピー・フォルシュングス−ウント・エントヴィックルングス−アクチェンゲゼルシャフト グリコシル化抗体
DE602004029455D1 (de) * 2004-07-20 2010-11-18 Altropus Gmbh Verwendung von Antikörpern in einer sehr geringen Dosis zur Impfung gegen Krebs
CN101355928B (zh) * 2005-04-26 2013-05-22 卫材R&D管理株式会社 用于癌症免疫疗法的组合物和方法
WO2007008943A2 (en) 2005-07-08 2007-01-18 Xencor, Inc. Optimized anti-ep-cam antibodies
EP1762575A1 (en) * 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
AT504231A1 (de) 2006-10-03 2008-04-15 Hans Dr Loibner Prädiktive parameter
BRPI0821165B8 (pt) 2007-12-07 2021-05-25 Nutricia Nv uso de uma composição
CA2744103C (en) * 2009-02-24 2018-01-02 Esbatech, An Alcon Biomedical Research Unit Llc Methods for identifying immunobinders of cell-surface antigens
US8887373B2 (en) 2012-02-24 2014-11-18 Covidien Lp Vessel sealing instrument with reduced thermal spread and method of manufacture therefor
US20140276968A1 (en) * 2013-03-14 2014-09-18 Ethicon, Inc. Applicator systems for surgical fasteners
US10196458B2 (en) * 2013-07-26 2019-02-05 The Regents Of The University Of California Anti-immunoglobulin E antibodies and methods of using thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341281C (en) * 1986-07-09 2001-08-07 Hubert J.P. Schoemaker Immunotherapy of tumor with monoclonal antibody against the 17-1a antigen
US5270202A (en) * 1989-11-03 1993-12-14 Syamal Raychaudhuri Anti-idiotypic antibodies to human melanoma-associated proteoglycan antigen
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5798100A (en) * 1994-07-06 1998-08-25 Immunomedics, Inc. Multi-stage cascade boosting vaccine
WO1997005597A1 (en) * 1995-07-31 1997-02-13 Litton Systems Canada Limited Flat panel pixel array incorporating photoconductive switches
EP0857176A1 (en) * 1995-10-25 1998-08-12 Centocor B.V. HUMAN EPITHELIAL ANTIGEN Ep-CAM DERIVED PEPTIDES AND THEIR USE
US6235280B1 (en) * 1996-04-12 2001-05-22 Malaya Chatterjee Methods of delaying development of CEA-associated tumors using anti-idiotype antibody 3H1
IL121041A0 (en) * 1997-06-09 1997-11-20 Yeda Res & Dev Immunogenic compositions for induction of anti-tumor immunity
US6274143B1 (en) * 1997-06-13 2001-08-14 Malaya Chatterjee Methods of delaying development of HMFG-associated tumors using anti-idiotype antibody 11D10
ATE480566T1 (de) * 1998-06-15 2010-09-15 Quest Pharmatech Inc Immuntherapeutische zusammensetzung und verfahren zur behandlung von prostatakrebs
MXPA01007148A (es) * 1999-01-13 2002-03-27 Igeneon Krebs Immuntherapie Uso de anticuerpos para vacunacion anti-cancer.
WO2001087233A2 (en) * 2000-05-16 2001-11-22 New York University Anti-idiotypic antibody against fimh adhesin of uropathogenic type i-fimbriated escherichia coli, compositions and method of use thereof

Also Published As

Publication number Publication date
PL201533B1 (pl) 2009-04-30
PT1140168E (pt) 2002-11-29
US20100233178A1 (en) 2010-09-16
HK1044487B (zh) 2005-09-16
EP1230932A3 (de) 2003-11-26
SK9642001A3 (en) 2002-03-05
NO329917B1 (no) 2011-01-24
PT1230932E (pt) 2005-04-29
NO20013093L (no) 2001-09-10
US7691372B2 (en) 2010-04-06
CN1344167A (zh) 2002-04-10
NZ512722A (en) 2003-07-25
PL364747A1 (en) 2004-12-13
EE200100366A (et) 2002-10-15
MXPA01007148A (es) 2002-03-27
ES2177509T3 (es) 2002-12-16
EP1230932B1 (de) 2005-01-12
ES2236375T3 (es) 2005-07-16
HUP0200527A2 (en) 2002-06-29
ID30223A (id) 2001-11-15
NO20013093D0 (no) 2001-06-21
IL144265A (en) 2006-08-20
EP1140168A1 (de) 2001-10-10
KR100771752B1 (ko) 2007-10-30
SK286627B6 (sk) 2009-02-05
ATE219687T1 (de) 2002-07-15
IL144265A0 (en) 2002-05-23
EE05474B1 (et) 2011-10-17
TR200102034T2 (tr) 2001-11-21
US20120003232A1 (en) 2012-01-05
US8444974B2 (en) 2013-05-21
EP1140168B1 (de) 2002-06-26
CA2360382C (en) 2011-05-24
WO2000041722A1 (de) 2000-07-20
CA2360382A1 (en) 2000-07-20
CN1188169C (zh) 2005-02-09
HK1044487A1 (en) 2002-10-25
AU2796400A (en) 2000-08-01
JP4774551B2 (ja) 2011-09-14
DE50000243D1 (de) 2002-08-01
AU768515B2 (en) 2003-12-18
CZ302801B6 (cs) 2011-11-16
IS5998A (is) 2001-07-10
HU226150B1 (en) 2008-05-28
DK1230932T3 (da) 2005-04-25
JP2002534481A (ja) 2002-10-15
ATE286745T1 (de) 2005-01-15
KR20010101446A (ko) 2001-11-14
CZ20012581A3 (cs) 2002-01-16
HRP20010526A2 (en) 2002-08-31
SI1140168T1 (en) 2002-10-31
DK1140168T3 (da) 2002-09-30
DE50009240D1 (de) 2005-02-17
EP1230932A2 (de) 2002-08-14
US20070224202A1 (en) 2007-09-27

Similar Documents

Publication Publication Date Title
PL364747A1 (en) Use of antibodies for anticancer vaccination
TR200001253T2 (tr) Tümöre özel antijenler
ATE402192T1 (de) Anti-ccr4 antikörper und fragmente davon
NZ527283A (en) Modified antibodies and methods of use
FR12C0004I2 (fr) Anticorps contre l'antigene ctla-4 humain et utilisation
ZA200609407B (en) Monoclonal antibodies to hepatocyte growth factor
NZ514228A (en) Method of Expressing Antigens on the Surface of Antigen Presenting Cells by Photochemical Internalisation
AU2002355677A1 (en) Antigenic polypeptides
AU2002352394A1 (en) Focussed antibody technology
PT1223980E (pt) Utilizacao de inibidores de csf-1
AU2342897A (en) Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody and use as a tumor vaccine and for targeting applications
WO2000020041A8 (en) Removal of preexisting antibodies to enhance the effectiveness of a therapeutic viral immunogenic agent
WO2000069915A3 (en) COMBINED APPROACH TO TREATMENT OF CANCER WITH hCG VACCINES
WO2004106379A8 (en) Immunotherapy of rectal cancer
IL160029A0 (en) Receptor, the use thereof, and mouse antibodies
WO2002038611A3 (en) Method of producing antibodies by immunization with conjugates of molecules coupled to charge-modified proteins
MXPA04000652A (es) Identificacion de antigenos especificos del tumor por medio de seleccion de bibliotecas de acido desoxirribonucleico complementario con sueros y uso de antigenos en tratamiento de tumores.
AU2002326318A1 (en) Targeting tumor cell antigens: antibodies useful for the diagnosis, prognosis, and treatment of cancer
BR0007814A (pt) Uso de anticorpos para a vacinação contra câncer
MY143402A (en) Preparations used in the treatment and prophilaxis of mycobacterial infections
ZA200200730B (en) Human monoclonal antibodies to prostate specific membrane antigen.